Infectious Disease Advisor news story
Among cisgender men and transgender women at increased risk for HIV-1 exposure, once-monthly oral islatravir demonstrates a safety profile similar to standard daily PrEP, while being associated with reductions in lymphocyte counts, according to study findings published in Clinical Infectious Diseases.
Investigators conducted a randomized, double-blind, phase 3 trial (IMPOWER-24) to assess the safety and tolerability of once-monthly oral islatravir compared with daily emtricitabine plus tenofovir disoproxil or tenofovir alafenamide for HIV prevention.
Read the full news story here.
/Infectious Disease Advisor requires free registration if more than 5 articles are viewed per month/
Source : Infectious Disease Adviso
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.